|Mr. Brendan McAtamney||CEO & Exec. Director||1.32M||N/A||54|
|Mr. Alan Ralph||CFO & Exec. Director||N/A||N/A||47|
|Mr. Chris Corbin||Exec. Director||N/A||N/A||62|
|Mr. Jez Moulding||Chief Operating Officer||N/A||N/A||N/A|
|Keith Byrne||Head of Investor Relations, Strategy & Corp. Communications||N/A||N/A||N/A|
UDG Healthcare plc, together with its subsidiaries, provides clinical, commercial, communication, and packaging services to the healthcare industry in the Republic of Ireland, the United Kingdom, North America, and continental Europe. It operates through three segments: Ashfield, Sharp, and Aquilant. The Ashfield segment offers commercialization and clinical services for the pharmaceutical and healthcare industry that comprise supporting healthcare professionals and patients at various stages of the product life cycle, as well as provides field and contact center sales teams, healthcare communications, patient support, audit, advisory, medical information, and event management services to approximately 300 healthcare companies. The Sharp segment provides contract and clinical trial packaging services for the pharmaceutical and biotechnology industries; and Track and Trace serialization services for various prescription drugs to have a unique serial code for authentication and traceability. The Aquilant segment engages in the sale, marketing, engineering, and distribution of medical and scientific devices in the areas of endoscopy, cardiology, radiology, surgical, and orthopaedics. The company was formerly known as United Drug plc and changed its name to UDG Healthcare plc in August 2013. UDG Healthcare plc was founded in 1948 and is based in Dublin, the Republic of Ireland.
UDG Healthcare plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.